Clinuvel Pharmaceuticals (ASX:CUV) logged AU$0.668 in EPS for fiscal 2026, compared with AU$0.718 a year ago, a Thursday filing showed.
For the 12 of months June 30, revenue was AU$94 million versus AU$95 million previously, the Australia-listed pharmaceutical company added.
The board declared a final dividend of AU$0.05 per share, unchanged from a year earlier, payable Sept. 18 to shareholders on record as of Sept. 4.
The biopharmaceutical company's shares rose nearly 2% in recent trading on Thursday.